摘要
目的:观察卡培他滨联合奥沙利铂(XELOX)方案与5-氟尿嘧啶/亚叶酸钙联合奥沙利铂(FOLFOX)方案同期调强适形放疗治疗复发和局部晚期直肠癌的疗效及不良反应。方法:回顾性分析62例复发或局部晚期直肠癌患者的临床病理资料。62例患者分为XELOX方案同期调强适形放疗组(简称XELOX组)32例,FOLFOX方案同期调强适形放疗组(简称FOLFOX组)30例,两组均化疗两周期以上。化疗同期调强适形放疗,两组放疗方式相同,均采用调强适形放疗,放疗剂量为60Gy～70Gy/33f～39f。按WHO标准评价客观疗效,RTOG及WHO标准评价放化疗的急性毒副反应。结果:XELOX组有效率78.1%,中位疾病无进展生存时间(PFS)为16月,1年生存率为87.5%;FOLFOX组有效率73.3%,中位疾病无进展生存时间(PFS)为18月,1年生存率为83.3%,两组差异无统计学意义(P>0.05)。不良反应中,手足综合征以XELOX组显著(P<0.05),余不良反应发生率以FOLFOX组稍高,但差异无统计学意义。结论:XELOX方案与FOLFOX方案同期调强适形放疗疗效确切,不良反应能耐受。两组疗效相似,不良反应XELOX组更低。
Objective： To evaluate the efficacy and toxicity of capecitabine plus oxaliplatin regimen （XELOX） versus 5-flu- orouracil/leucovorin plus oxaliplatin （FOLFOX） combined with intensity modulated radiation therapy （IMRT） in the treatment of lo- cally recurrent and advanced rectal cancer. Methods ： Total of 62 cases with locally recurrent and advanced rectal cancer were enrolled into this study, 32 patients and 30 patients were divided into XELOX regimen combined with IMRT group and FOLFOX regimen com- bined with IMRT group respectively. All patients received two cycles of chemotherapy at least. Concurrent IMRT was given in all the cases by irradiating with 60 - 70Gy/33 - 39f. The efficacy were evaluated according to WHO standard and the toxicity were evaluated according to RTOG and WHO standard. Results： The overall response rate was 78.1% in XELOX group of 32 cases and 73.3% in FOLFOX group of 30 cases. The median PFS and 1-year survial for XELOX group and FOLFOX group were 16 months, 87.5% and 18 months,83.3% respectively. The difference was not statistically significant between the two groups（ P 〉 0. 05 ）. The incidence of hand and foot syndrome in XELOX group was more obvious than in FOLFOX group（ P 〈 0. 05 ）. Incidence of other side effects in FOLFOX group was higher than that of those in XELOX group, but no significant difference existed. Conclusion： Both of the two methods are feasible ,well tolerated and effective in the treatment of locally recurrent and advanced rectal cancer. The efficacy in two groups is similar,and the side effects in XELOX group is lower than in FOLFOX group.
出处
《肿瘤预防与治疗》
2011年第2期99-102,共4页
Journal of Cancer Control And Treatment
